Smith & Nephew SNATS (NYSE:SNN) Upgraded to Strong-Buy at Kepler Capital Markets
Kepler Capital Markets upgraded Smith & Nephew SNATS (NYSE:SNN) to a "strong-buy" rating. Other analysts have mixed ratings, with one downgrading to "buy" and others maintaining "hold" ratings. The stock has a consensus price target of $35.75. Institutional investors have shown increased interest in the company. Smith & Nephew SNATS operates in medical devices, focusing on orthopaedics, sports medicine, and advanced wound management.
Smith & Nephew SNATS (NYSE:SNN - Get Free Report) was upgraded by Kepler Capital Markets to a "strong-buy" rating in a report issued on Monday,Zacks.com reports.
- Santa Rally comes early for these stocks
Other equities analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a research report on Friday, October 3rd. Canaccord Genuity Group dropped their price target on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a "hold" rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings restated a "hold (c+)" rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Sanford C. Bernstein set a $37.50 target price on Smith & Nephew SNATS and gave the stock a "market perform" rating in a research report on Tuesday, October 14th. Finally, Royal Bank Of Canada reissued an "outperform" rating on shares of Smith & Nephew SNATS in a research note on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $35.75.
Get Smith & Nephew SNATS alerts:
Read Our Latest Stock Report on Smith & Nephew SNATS
Smith & Nephew SNATS Stock Performance
- Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand
Smith & Nephew SNATS stock opened at $32.56 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00. The business has a 50 day simple moving average of $35.79 and a 200-day simple moving average of $33.16. Smith & Nephew SNATS has a 12 month low of $23.69 and a 12 month high of $38.79.
Institutional Investors Weigh In On Smith & Nephew SNATS
Institutional investors have recently modified their holdings of the company. Cerity Partners LLC increased its stake in Smith & Nephew SNATS by 207.3% in the 1st quarter. Cerity Partners LLC now owns 31,020 shares of the medical equipment provider's stock valued at $880,000 after purchasing an additional 20,926 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Smith & Nephew SNATS in the first quarter valued at $570,000. Cetera Investment Advisers increased its position in shares of Smith & Nephew SNATS by 8.9% in the first quarter. Cetera Investment Advisers now owns 16,748 shares of the medical equipment provider's stock valued at $475,000 after buying an additional 1,373 shares in the last quarter. Richards Merrill & Peterson Inc. raised its stake in shares of Smith & Nephew SNATS by 500.0% during the 1st quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock worth $34,000 after buying an additional 1,000 shares during the last quarter. Finally, Pinnacle West Asset Management Inc. boosted its position in shares of Smith & Nephew SNATS by 10.9% in the 1st quarter. Pinnacle West Asset Management Inc. now owns 10,175 shares of the medical equipment provider's stock worth $289,000 after buying an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 25.64% of the company's stock.
Smith & Nephew SNATS Company Profile
(Get Free Report)- 3 Healthcare Dividend Payers With Big Price Growth
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Read More
- Five stocks we like better than Smith & Nephew SNATS
- Russell 2000 Index, How Investors Use it For Profitable Trading
- What’s on the Thanksgiving Table? A Stock Pick for Every Course
- There Are Different Types of Stock To Invest In
- Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain
- What to Know About Investing in Penny Stocks
- Qualcomm’s Bulls Are Running Out of Room to Be Wrong
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Smith & Nephew SNATS Right Now?
Before you consider Smith & Nephew SNATS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.
While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
